Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls

• Argus upgraded Bristol Myers (BMY) to Buy from Hold with a $75 terms target. Bristol Myers is showing signs of a turnaround arsenic maturation products and caller launches amended margins, portion raised 2026 net guidance and imaginable M&A involvement from AstraZeneca (AZN) supply further upside catalysts, the steadfast tells investors successful a probe note.

• Freedom Broker upgraded McDonald's (MCD) to Buy from Hold with a terms people of $305, down from $320. The institution reported softer than expected gross and weaker comparable income maturation successful the U.S., the steadfast tells investors successful a probe note.

• Morgan Stanley upgraded Humana (HUM) to Equal Weight from Underweight with a terms people of $370, up from $249. The steadfast cites improving visibility into Medicare Advantage outgo trends for the upgrade.

• JPMorgan upgraded Expeditors (EXPD) to Neutral from Underweight with a terms people of $200, up from $144. The steadfast believes Expeditors' momentum should beryllium further supported by an "unprecedented restructuring effort" by its caller management.

• Bernstein upgraded Elf Beauty (ELF) to Outperform from Market Perform with a terms people of $113, up from $60. The steadfast believes the institution has the "most applicable operating exemplary for today's consumer" with societal media fluency, "rapid innovation cycles, and a viral-prone attack to caller merchandise development."

Top 5 Downgrades:

• Jefferies downgraded Best Buy (BBY) to Hold from Buy with a terms people of $85, down from $89. The steadfast says user acquisition intentions for Best Buy "reveal a wide downshift" successful July, which does not bode good for the hardest comparison of 2026 successful Q3.

• Stifel downgraded TransDigm (TDG) to Hold from Buy with a terms people of $1,405, down from $1,525. The steadfast views the company's fiscal Q3 study arsenic beardown but sees "rising risks" holding backmost the stock's valuation.

• Citi downgraded Burlington Stores (BURL) to Neutral from Buy with an unchanged terms people of $380. The steadfast cites valuation for the downgrade with the shares adjacent the terms target.

• UBS downgraded FIS (FIS) to Neutral from Buy with a terms people of $49, down from $63. The steadfast cites the company's reduced 2026 gross and profitability guidance for the downgrade.

• Freedom Broker downgraded Illumina (ILMN) to Hold from Buy with a terms people of $185, up from $155. The steadfast says the company's "strong 4th reinforces Illumina's accelerating cardinal maturation story," but believes overmuch of the upside is priced successful astatine existent stock levels.